Revealing metastatic castration‐resistant prostate cancer master regulator through lncRNAs‐centered regulatory network
Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) is an aggressive form of cancer unresponsive to androgen deprivation therapy (ADT) that spreads quickly to other organs. Despite reduced androgen levels after ADT, mCRPC development and lethality continues to be conducted by...
Main Authors: | Rafaella Sousa Ferraz, João Vitor Ferreira Cavalcante, Leandro Magalhães, Ândrea Ribeiro‐dos‐Santos, Rodrigo Juliani Siqueira Dalmolin |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-09-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.6481 |
Similar Items
-
Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer
by: Joshua P. Schiff, et al.
Published: (2019-05-01) -
Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
by: Mathieu Gaudreault, et al.
Published: (2023-03-01) -
Immunotherapy in patients with metastatic castration-resistant prostate cancer: a meta-analysis of data from 7 phase III studies and 3 phase II studies
by: Anqiang Zhang, et al.
Published: (2022-09-01) -
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
by: Iván Henríquez, et al.
Published: (2021-09-01) -
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients
by: Murali Kesavan, et al.
Published: (2021-03-01)